{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:58:07Z","timestamp":1785308287091,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s40121-024-01004-2","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T11:01:32Z","timestamp":1719399692000},"page":"1807-1819","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Characterizing Day 1 Area Under the Curve Following Vancomycin Loading Dose Administration in Adult Hospitalized Patients Using Non-Trapezoidal Linear Pharmacokinetic Equations: A Retrospective Observational Study"],"prefix":"10.1007","volume":"13","author":[{"given":"Abdulwhab","family":"Shremo Msdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinda C.","family":"Abdul-Mutakabbir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen K.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"key":"1004_CR1","unstructured":"Bauer LA. In: Applied clinical pharmacokinetics, 3rd Ed. In: Vancomycin. New York: McGraw-Hill Medical; 2015. Accessed on Jan 21, 2024."},{"issue":"11","key":"1004_CR2","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835\u201364.","journal-title":"Am J Health Syst Pharm"},{"issue":"5","key":"1004_CR3","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/cid\/ciu398","volume":"59","author":"TP Lodise","year":"2014","unstructured":"Lodise TP, Drusano GL, Zasowski E, Dihmess A, Lazariu V, Cosler L, et al. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough? Clin Infect Dis. 2014;59(5):666\u201375.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1004_CR4","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1128\/AAC.03970-14","volume":"59","author":"AM Casapao","year":"2015","unstructured":"Casapao AM, Lodise TP, Davis SL, Claeys KC, Kullar R, Levine DP, et al. Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis. Antimicrob Agents Chemother. 2015;59(6):2978\u201385.","journal-title":"Antimicrob Agents Chemother"},{"key":"1004_CR5","unstructured":"Timothy J. Bensman PMB. Winter\u2019s basic clinical pharmacokinetics \/ Paul Beringer, PharmD, Associate Professor, University of Southern California, Los Angeles, CA. . In: Vosburgh MHA, editor. Winter's Basic Clinical Pharmacokinetics Sixth edition. Philadelphia Lippincott Williams & Wilkins, a Wolters Kluwer business 2018."},{"key":"1004_CR6","volume-title":"Clinical pharmacokinetics and pharmacodynamics: concepts and applications, fourth edition clinical pharmacokinetics: concepts and applications, 4e","author":"MRTN Tozer","year":"2011","unstructured":"Tozer MRTN. Clinical pharmacokinetics and pharmacodynamics: concepts and applications, fourth edition clinical pharmacokinetics: concepts and applications, 4e. Philadelphia: Lippincott Williams & Wilkins, a Wolters Kluwer business; 2011."},{"key":"1004_CR7","volume-title":"Applied biopharmaceutics & pharmacokinetics, 7e","author":"RC Siwale","year":"2016","unstructured":"Siwale RC, Sani SN. Multiple-dosage regimens. In: Shargel L, Yu ABC, editors. Applied biopharmaceutics & pharmacokinetics, 7e. New York: McGraw-Hill Education; 2016."},{"issue":"11","key":"1004_CR8","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1093\/jac\/dkab278","volume":"76","author":"CJ Hodiamont","year":"2021","unstructured":"Hodiamont CJ, Juffermans NP, Berends SE, van Vessem DJ, Hakkens N, Math\u00f4t RAA, et al. Impact of a vancomycin loading dose on the achievement of target vancomycin exposure in the first 24 h and on the accompanying risk of nephrotoxicity in critically ill patients. J Antimicrob Chemother. 2021;76(11):2941\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"1004_CR9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3947\/ic.2020.52.4.573","volume":"52","author":"M Pongchaidecha","year":"2020","unstructured":"Pongchaidecha M, Changpradub D, Bannalung K, Seejuntra K, Thongmee S, Unnual A, et al. Vancomycin area under the curve and pharmacokinetic parameters during the first 24 hours of treatment in critically ill patients using Bayesian forecasting. Infect Chemother. 2020;52(4):573\u201382.","journal-title":"Infect Chemother"},{"key":"1004_CR10","volume-title":"Applied biopharmaceutics & pharmacokinetics, 7e","author":"H Zheng","year":"2016","unstructured":"Zheng H. Intravenous infusion. In: Shargel L, Yu ABC, editors. Applied biopharmaceutics & pharmacokinetics, 7e. New York: McGraw-Hill Education; 2016."},{"issue":"9","key":"1004_CR11","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1310\/hpj4409-751","volume":"44","author":"CA Deryke","year":"2009","unstructured":"Deryke CA, Alexander DP. Optimizing vancomycin dosing through pharmacodynamic assessment targeting area under the concentration-time curve\/minimum inhibitory concentration. Hosp Pharm. 2009;44(9):751\u201365.","journal-title":"Hosp Pharm"},{"issue":"12","key":"1004_CR12","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1002\/phar.2486","volume":"40","author":"AH Flannery","year":"2020","unstructured":"Flannery AH, Delozier NL, Effoe SA, Wallace KL, Cook AM, Burgess DS. First-dose vancomycin pharmacokinetics versus empiric dosing on area-under-the-curve target attainment in critically ill patients. Pharmacotherapy. 2020;40(12):1210\u20138.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"1004_CR13","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/cpt1977213362","volume":"21","author":"RJ Sawchuk","year":"1977","unstructured":"Sawchuk RJ, Zaske DE, Cipolle RJ, Wargin WA, Strate RG. Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther. 1977;21(3):362\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"1004_CR14","first-page":"1245815","volume":"2016","author":"B Shahrami","year":"2016","unstructured":"Shahrami B, Najmeddin F, Mousavi S, Ahmadi A, Rouini MR, Sadeghi K, et al. Achievement of vancomycin therapeutic goals in critically ill patients: early individualization may be beneficial. Crit Care Res Pract. 2016;2016:1245815.","journal-title":"Crit Care Res Pract"},{"key":"1004_CR15","unstructured":"Taskforce SVT. Vancomycin Area Under the Curve (AUC) Dosing Guideline Template for Institution Adaptation 2021 [Available from: https:\/\/sidp.org\/Vancomycin-AUC-Implementation-Toolkit-Guide. Accessed on Jan 29, 2024."},{"issue":"4","key":"1004_CR16","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/phar.2670","volume":"42","author":"KB Olney","year":"2022","unstructured":"Olney KB, Wallace KL, Mynatt RP, Burgess DS, Grieves K, Willett A, et al. Comparison of Bayesian-derived and first-order analytic equations for calculation of vancomycin area under the curve. Pharmacotherapy. 2022;42(4):284\u201391.","journal-title":"Pharmacotherapy"},{"issue":"6","key":"1004_CR17","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1177\/0897190019834369","volume":"33","author":"ER Gregory","year":"2020","unstructured":"Gregory ER, Burgess DR, Cotner SE, VanHoose JD, Flannery AH, Gardner B, et al. Vancomycin area under the curve dosing and monitoring at an academic medical center: transition strategies and lessons learned. J Pharm Pract. 2020;33(6):774\u20138.","journal-title":"J Pharm Pract"},{"issue":"9","key":"1004_CR18","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1002\/jcph.1273","volume":"58","author":"J Truong","year":"2018","unstructured":"Truong J, Smith SR, Veillette JJ, Forland SC. Individualized pharmacokinetic dosing of vancomycin reduces time to therapeutic trough concentrations in critically ill patients. J Clin Pharmacol. 2018;58(9):1123\u201330.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1004_CR19","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"key":"1004_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95: 103208.","journal-title":"J Biomed Inform"},{"issue":"4","key":"1004_CR21","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1128\/AAC.21.4.575","volume":"21","author":"RA Blouin","year":"1982","unstructured":"Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO Jr. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother. 1982;21(4):575\u201380.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1004_CR22","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/00007691-199410000-00013","volume":"16","author":"MP Ducharme","year":"1994","unstructured":"Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit. 1994;16(5):513\u20138.","journal-title":"Ther Drug Monit"},{"issue":"5","key":"1004_CR23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2165\/00003088-200038050-00003","volume":"38","author":"DT Bearden","year":"2000","unstructured":"Bearden DT, Rodvold KA. Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics. Clin Pharmacokinet. 2000;38(5):415\u201326.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"1004_CR24","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/j.1552-4604.1993.tb01922.x","volume":"33","author":"DR Guay","year":"1993","unstructured":"Guay DR, Vance-Bryan K, Gilliland S, Rodvold K, Rotschafer J. Comparison of vancomycin pharmacokinetics in hospitalized elderly and young patients using a Bayesian forecaster. J Clin Pharmacol. 1993;33(10):918\u201322.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1004_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/phar.1531","volume":"35","author":"ED Adane","year":"2015","unstructured":"Adane ED, Herald M, Koura F. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections. Pharmacotherapy. 2015;35(2):127\u201339.","journal-title":"Pharmacotherapy"},{"issue":"5","key":"1004_CR26","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/phar.1588","volume":"35","author":"J Hong","year":"2015","unstructured":"Hong J, Krop LC, Johns T, Pai MP. Individualized vancomycin dosing in obese patients: a two-sample measurement approach improves target attainment. Pharmacotherapy. 2015;35(5):455\u201363.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"1004_CR27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1128\/AAC.25.4.433","volume":"25","author":"GR Matzke","year":"1984","unstructured":"Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother. 1984;25(4):433\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1004_CR28","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1093\/cid\/ciz051","volume":"69","author":"DM Aljefri","year":"2019","unstructured":"Aljefri DM, Avedissian SN, Rhodes NJ, Postelnick MJ, Nguyen K, Scheetz MH. Vancomycin area under the curve and acute kidney injury: a meta-analysis. Clin Infect Dis. 2019;69(11):1881\u20137.","journal-title":"Clin Infect Dis"},{"issue":"24","key":"1004_CR29","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.2146\/ajhp180034","volume":"75","author":"EL Heil","year":"2018","unstructured":"Heil EL, Claeys KC, Mynatt RP, Hopkins TL, Brade K, Watt I, et al. Making the change to area under the curve-based vancomycin dosing. Am J Health Syst Pharm. 2018;75(24):1986\u201395.","journal-title":"Am J Health Syst Pharm"},{"issue":"12","key":"1004_CR30","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1093\/ajhp\/zxz070","volume":"76","author":"WD Kufel","year":"2019","unstructured":"Kufel WD, Seabury RW, Mogle BT, Beccari MV, Probst LA, Steele JM. Readiness to implement vancomycin monitoring based on area under the concentration\u2013time curve: a cross-sectional survey of a national health consortium. Am J Health Syst Pharm. 2019;76(12):889\u201394.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"1004_CR31","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1128\/AAC.01653-13","volume":"58","author":"MN Neely","year":"2014","unstructured":"Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, et al. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother. 2014;58(1):309\u201316.","journal-title":"Antimicrob Agents Chemother"},{"key":"1004_CR32","first-page":"204993612110059","volume":"8","author":"AH Flannery","year":"2021","unstructured":"Flannery AH, Wallace KL, Rhudy CN, Olmsted AS, Minrath RC, Pope SM, et al. Efficacy and safety of vancomycin loading doses in critically ill patients with methicillin-resistant Staphylococcus aureus infection. Ther Adv Infect Dis. 2021;8:20499361211005964.","journal-title":"Ther Adv Infect Dis"},{"key":"1004_CR33","volume-title":"Applied biopharmaceutics & pharmacokinetics, 7e","author":"MP Ducharme","year":"2016","unstructured":"Ducharme MP. Drug elimination, clearance, and renal clearance. In: Shargel L, Yu ABC, editors. Applied biopharmaceutics & pharmacokinetics, 7e. New York: McGraw-Hill Education; 2016."},{"issue":"4","key":"1004_CR34","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/j.1875-9114.1996.tb03657.x","volume":"16","author":"JE Murphy","year":"1996","unstructured":"Murphy JE, Winter ME. Clinical pharmacokinetic pearls: bolus versus infusion equations. Pharmacotherapy. 1996;16(4):698\u2013700.","journal-title":"Pharmacotherapy"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01004-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-024-01004-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01004-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T17:06:54Z","timestamp":1721754414000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-024-01004-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1004"],"URL":"https:\/\/doi.org\/10.1007\/s40121-024-01004-2","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]},"assertion":[{"value":"9 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jacinda Abdul-Mutakabbir is an Advisory Board member of Infectious Diseases and Therapy. Jacinda Abdul-Mutakabbir was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Jacinda Abdul-Mutakabbir received an honorarium from Shionogi, GSK, NovaVax, CSL Sequiris, Innoviva Specialty Therapeutics, and AbbVie. She has also received research support from CSL Sequiris. All other authors (Abdulwhab Shremo Msdi and Karen K. Tan) have no conflicts to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration. The LLUMC Institutional Review Board approved this study (#5210270) and the waiver of informed consent, given the minimal risk and retrospective nature of the study design.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}